<DOC>
	<DOCNO>NCT01602939</DOCNO>
	<brief_summary>The aim study evaluate efficacy term clinical biological response rate Cladribine plus Pegylated Interpheron alpha-2a therapy patient advance systemic mastocytosis carry D816V exon 17 KIT mutation .</brief_summary>
	<brief_title>Cladribine Plus Pegylated Interpheron Alfa-2a Systemic Mastocytosis</brief_title>
	<detailed_description />
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Age old 18 year . Diagnosis advance systemic mastocytosis ( aggressive systemic mastocytosis proggressing systemic mastocytosis ) D816V exon 17 KIT mutation . ECOG ≤ 3 . Signed informed consent . Impaired liver function ( total bilirubin ≥ 2.0 mg/dl , AST ALT &gt; 3 x upper limit normal ) relate mastocytosis . Impaired renal function ( ≥ 2.0 mg/dL ) relate mastocytosis . Grade IIIIV cytopenia relate mastocytosis . Severe cardiopathy ( grade III/IV NYHA , leave ventricular ejection fraction &lt; 50 % ) . Pregnancy breastfeed . Female patient use contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mast cell</keyword>
	<keyword>Mastocytosis</keyword>
	<keyword>Mast cell disease</keyword>
</DOC>